6 assets in Chronic Eosinophilic Leukemia

Therapeutic assets addressing Chronic Eosinophilic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Azacitidine Chronic Eosinophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Pevonedistat Chronic Eosinophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
Venetoclax Chronic Eosinophilic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)